Skip to content

VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning

VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02224352
Enrollment
54
Registered
2014-08-25
Start date
2014-07-31
Completion date
2022-03-31
Last updated
2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Weaning Failure

Keywords

Electric Stimulation, Respiration, Abdominal wall, Lung Diseases, Respiratory Tract Diseases, COPD

Brief summary

Background: Over one million patients in the US are estimated to undergo mechanical ventilation every year, and approximately 300,000 of them fail attempts at weaning. The morbidity and mortality of these patients is greater than in patients who are successfully weaned. It follows that treatments aimed at reducing the duration of mechanical ventilation have the potential to benefit society both in terms of human suffering and cost. Patients who fail attempts at weaning assist their inspiratory muscles during inhalation by recruiting their expiratory muscles during exhalation. Unfortunately, this recruitment occurs relatively late during a weaning trial. The knowledge that (a) expiratory muscle recruitment can assist inspiration, (b) the recruitment of the expiratory muscles is delayed during weaning, and (c) that the respiratory muscles in patients requiring mechanical ventilation are in a catabolic state raises the possibility that strategies designed to produce an early recruitment, and improve the strength, of the expiratory muscles could improve weaning outcomes in difficult to wean patients. The current investigation, which will be conducted in healthy subjects and in ambulatory patients with chronic obstructive pulmonary disease (COPD) at Edward Hines Jr. VAH (Aims 1 and 2), and in patients who are difficult to wean from mechanical ventilation at RML Specialty Hospital, Hinsdale, IL (Aim 3), has been designed to develop and assess a novel triggering algorithm (VentFree), that controls the delivery of non-invasive neuro muscular electrical stimulation (NMES) to the abdominal-wall muscles during exhalation, and to study the physiological (respiratory) responses to such stimulation in assisting respiration in healthy subjects, in ambulatory patients with COPD and in patients requiring pronged mechanical ventilation.

Interventions

Sponsors

RML Specialty Hospital
CollaboratorOTHER
Edward Hines Jr. VA Hospital
Lead SponsorFED

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Aim 1 and Aim 2:Healthy Subjects and Ambulatory COPD Patients Studied at Hines VAH Healthy subjects (Hines VAH), Inclusion criteria: * Age ≥ 18 years * No history of acute or chronic respiratory disease, cardiac or neuromuscular disease. Ambulatory COPD patients (Hines VAH), Inclusion criteria: * Age ≥ 18 years * Chronic airway obstruction defined as forced expiratory volume in one second (FEV1) of 70% predicted or less, ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) of 0.7 or less * Stable clinical condition without an exacerbation during the preceding four weeks Aim 3: Patients being weaned from prolonged mechanical ventilation (RML Specialty Hospital), Inclusion criteria: * Age ≥ 18 years * History of neuromuscular disease * Body mass index \> 35 kg/m2 * Patients who have received mechanical ventilation for at least 14 days and the primary physician judges the patient is ready to start weaning * Able to breathe spontaneously for more than 5 minutes and less than 12 hours * Clinically stable: oxygen saturation \> 90% with a fractional inspired oxygen ≤ 0.40, external PEEP ≤ 5 cm H2O, temperature ranging from 35.5 to 38.5Co, no intravenous administration of vasoactive agents. Additional inclusion/

Exclusion criteria

for all potential participants * Subjects with implanted electronic devices - such as cardiac pacemakers, defibrillators and intrathecal pumps - will be excluded because NMES could cause malfunction of those devices. * Only subjects with intact abdominal-wall skin will be enrolled because NMES can cause discomfort when applied over skin that is irritated or on open wounds. * Pregnancy will be a contraindication to participate in the study because it is unknown whether the application of NMES to the abdominal or lumbar area during pregnancy may produce adverse effects. * Unable to comprehend and interact in English.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity10 minutes of resting breathingNumber of breaths that are correctly stimulated during exhalation over the total number of breaths taken.
Error rate10 minutes of resting breathingNumber of false positive stimulation triggers over the total number of breaths taken.

Secondary

MeasureTime frame
Minute ventilation10 minutes of resting breathing
Esophageal pressure time product10 minutes of resting breathing
Tidal volume10 minutes of resting breathing
Tension time index of the diaphragm10 minutes of resting breathing
Ratio of tidal change in Pga to tidal change in Pes10 minutes of resting breathing
Trans diaphragmatic pressure time product10 minutes of resting breathing
Respiratory rate10 minutes of resting breathing

Countries

United States

Contacts

Primary ContactFranco Laghi, MD
Franco.Laghi@va.gov708/202-2705
Backup ContactHameeda Shaikh, MD
Hameeda.Shaikh@va.gov708/202-2705

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026